Article thumbnail

Expression of Human Globular Adiponectin-Glucagon-Like Peptide-1 Analog Fusion Protein and Its Assay of Glucose-Lowering Effect In Vivo

By Tongfeng Zhao, Jing Lv, Jiangpei Zhao, Xiao Huang and Haijuan Xiao

Abstract

In this study, human globular adiponectin-glucagon-like peptide-1 analog (gAd-GLP-1-A) fusion protein was expressed and its glucose-lowering effect was measured in vivo. We constructed a prokaryotic expression vector PET28a-gAd-GLP-1-A and transformed the vector into Escherichia coli BL21 (DE3). A recombinant fusion protein of about 25KD was expressed from BL21 (DE3) cells after isopropylthio-β-D-galactoside induction. This protein was N-terminal His-tagged gAd-GLP-1-A fusion protein. Most of the protein was expressed in inclusion body. The fusion protein in inclusion body was purified by using High-Affinity Nickel Iminodiacetic Acid Resin and refolded in urea gradient refolding buffer. The refolded protein was incubated with enterokinase to remove the N-terminal His-tag. The fusion protein without His-tag is gAd-GLP-1-A fusion protein, which exhibited significant glucose-lowering effect in diabetic mice

Topics: Research Paper
Publisher: Ivyspring International Publisher
OAI identifier: oai:pubmedcentral.nih.gov:3053492
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2005). Adiponectin: action, regulation and association to i nsulin sensitivity. Obes Rev.
  2. (2003). Cloning and expression of adiponectin and its globular domain, and measurement of the biological activity in vivo. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai).
  3. (1993). Cloning and functional expression of a cDNA encoding the catalytic subunit of bovine enterokinase.
  4. Control of protein functional dynamics by peptide linkers.
  5. (1998). Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
  6. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.
  7. (2007). Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes.
  8. (2008). GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring).
  9. (2008). Glucagon-like peptide 1 based therapy for type 2 diabetes.
  10. (2003). Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem.
  11. (2002). Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes.
  12. (2006). Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. J Pharmacol Exp Ther.
  13. (2007). One-step purification of a fusion protein of glucagon-like peptide-1 and human serum albumin expressed in pichia pastoris by an immunomagnetic separation technique. Biosci Biotechnol Biochem.
  14. (2008). Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab.
  15. (1995). Purification of His-Tag fusion proteins from Escherichia coli. Trends Biochem Sci.
  16. (1993). Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res.
  17. (2006). Zhan Yuhong, Gu Wei. Construction of human globular adiponectin-glucagons-like peptide-1 fusion protein expression vector. Chongqing Medical.